PMN logo

PROMIS NEUROSCIENCES INC

PMNNASDAQ
πŸ† #4422 by market capEarnings Mar 23 Β· PostUS Equity
$3.16β–Ό $0.05 (βˆ’1.56%)
Market closed Β· at close
πŸ””
Track PMN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.6%
7dβ–Ό 4.4%
14dβ–Ό 22.7%
30dβ–Ό 63.1%
ytdβ–Ό 54.8%
1yβ–Ό 70.6%
🏦Market Cap
$28M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
2888.0x
Expensive
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$3.03 – $3.17
52-Week Range
$2.78 – $27.40
Volume (shares)
109,911
Avg Volume (shares)
β€”
Shares Outstanding
9.0M
Next Earnings
2027-03-23

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
2888.0x
EPS (TTM)
$-12.61
Dividend Yield
β€”
Dilution (1yr)
+26.2%
PMN logo

PROMIS NEUROSCIENCES INC

PMN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$40Mβ–² +138.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$28Mβ–² +3.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.8Mβ–² +26.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6Mβ–Ό βˆ’$7M YoY
StockOtter Β· stockotter.space

About PROMIS NEUROSCIENCES INC

ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
11 analysts
Strong Buy2
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

GlobeNewsWireΒ·5d ago

ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline

TXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by Ossianix

GlobeNewsWireΒ·10d ago

ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing

PRECISE-AD Phase 1b clinical trial in Alzheimer's patients remains on track for unblinded 12-month topline data in the first quarter of 2027, including full safety, biomarker and cognitive outcomes data PMN310 binds sele

GlobeNewsWireΒ·17d ago

ProMIS Neurosciences to Participate in Upcoming Conferences in November

CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neur

Zacks Investment ResearchΒ·18d ago

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

Four biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.

GlobeNewsWireΒ·19d ago

ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026

Cambridge, Massachusetts, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins

Zacks Investment ResearchΒ·24d ago

Wall Street Analysts Believe Promis Neurosciences (PMN) Could Rally 292.95%: Here's is How to Trade

The mean of analysts' price targets for Promis Neurosciences (PMN) points to a 293% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raisi